HER3 functions as an effective therapeutic target in triple negative breast cancer to potentiate the antitumor activity of gefitinib and paclitaxel.

Autor: Lyu, Hui1 (AUTHOR), Shen, Fei2 (AUTHOR), Ruan, Sanbao1 (AUTHOR), Tan, Congcong1 (AUTHOR), Zhou, Jundong3 (AUTHOR), Thor, Ann D.4 (AUTHOR), Liu, Bolin1 (AUTHOR) bliu2@lsuhsc.edu
Zdroj: Cancer Cell International. 9/16/2023, Vol. 23 Issue 1, p1-16. 16p.
Databáze: Academic Search Ultimate
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje